Frontiers in Endocrinology · Nov 15, 2026
A role for the central nervous system to integrate peripheral glucagon receptor signaling
By Jonathan D. Douros, Connor Mahler
Unimolecular agonists of the glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors (GCGR) have emerged as the most effective weight-reducing pharmacotherapies to date. Of the three target receptors, GCGR agonism is perhaps the most counterintuitive. Antagonists of the receptor were pursued for type 2 diabetes given its known effects to elevate glycemia until factors including on-target pharmacologic liabilities, rising obesity prevalence, and novel molecular tools reframed the GCGR as a metabolic disease target. Selective, long-acting GCGR agonists subsequently established increased energy expenditure rather than appetite suppression as a differentiated mechanism of action compared to GLP-1R and GIPR. Here, we propose a model whereby GCGR agonism generates metabolic demand by driving hepatic fatty acid oxidation to fuel gluconeogenesis and ureagenesis. We posit initial oxidation of hepatic lipids gives way to an interorgan nutrient cycle in which adipose tissue stores are liberated for use in the liver. This cycle appears to require integration by the central nervous system, specifically the medial basal hypothalamic GABAergic neurons via hepatic fibroblast growth factor 21 and, potentially, hepatic vagal afferents. This architecture explains how GCGR agonism contributes energy expenditure to triagonist efficacy and defines tractable paths for probing the model.